LINZESS (linaclotide) is not currently available as a generic drug. However, there are ongoing patent challenges that could impact its market exclusivity in the future.
When Does LINZESS Patent Exclusivity End?
The primary patents protecting LINZESS are set to expire in the coming years. For example, one key patent is expected to expire around 2027, though this can be subject to extensions and legal challenges [1]. The exact timeline for patent expiry can be complex and may vary depending on specific patent families and jurisdictions.
Who is Challenging LINZESS Patents?
Companies seeking to market generic versions of drugs often challenge existing patents. While specific details about ongoing litigation are not always public, such challenges are a common part of the process for bringing generic medications to market [2].
What Happens After LINZESS Patents Expire?
Once patent exclusivity ends and any associated market protection periods are concluded, generic manufacturers can seek approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) to market their own versions of the drug. This typically leads to increased competition and lower prices for consumers. DrugPatentWatch.com tracks patent expirations and related legal proceedings for many drugs, including LINZESS [1].
How Does LINZESS Work?
LINZESS is a guanylate cyclase-C (GC-C) agonist. It works by acting on the lining of the intestine. It increases the secretion of chloride and bicarbonate into the intestinal lumen, which leads to increased fluid in the intestines. This helps to soften stool and increase bowel movement frequency. It also reduces visceral hypersensitivity, which can help alleviate abdominal pain associated with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [3].